Machine signal
Active cluster sell — 4 distinct insiders, $16.9M, window ends Oct 1, 2026.
Figures computed from official regulatory filings — .
Analysttarget 120.21 USD (+29%) · consensus 4.82/5 · 16 buy · 1 hold · 0 sell
Ownershipinsiders 1.67% · institutions 111.46% · short 14.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Spyre Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
48 buys107 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Burrows Scott L | Sell | $285.4K | SEC |
| King-Jones Heidy | Sell | $243K | SEC |
| Burrows Scott L | Sell | $193K | SEC |
| Turtle Cameron | Sell | $241.4K | SEC |
| King-Jones Heidy | Exercise | $419.5K | SEC |
| Burrows Scott L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burrows Scott L | Exercise | $108.8K | SEC |
| King-Jones Heidy | Sell | $660.3K | SEC |
| Turtle Cameron | Sell | $9.4K | SEC |
| Turtle Cameron | Sell | $465.9K | SEC |
| King-Jones Heidy | Sell | $1.5M | SEC |
| Burrows Scott L | Sell | $1.6M | Unusual size | SEC |
| Turtle Cameron | Sell | $368.2K | SEC |
| Burrows Scott L | Exercise | $253.8K | Unusual size | SEC |
| Turtle Cameron | Sell | $53.5K | SEC |
| Burrows Scott L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Turtle Cameron | Sell | $241.7K | SEC |
| Burrows Scott L | Sell | $53.4K | SEC |
| King-Jones Heidy | Sell | $35.7K | SEC |
| Burrows Scott L | Sell | $135.4K | SEC |
| Burrows Scott L | Sell | $21.4K | SEC |
| King-Jones Heidy | Sell | $194.7K | SEC |
| King-Jones Heidy | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burrows Scott L | Sell | $1.6M | Unusual size | SEC |
| Turtle Cameron | Sell | $325.8K | SEC |